MedWatch

Analyst: New Lundbeck drugs are the bright spot of the report

The most recent quarterly financial report from Lundbeck points in the right direction in regards to traversing the dreaded patent cliff, according to an analyst.

Foto: Lundbeck, PR

Practically all of Lundbeck’s products sold more than expected by analysts in Q2 2013, but it is especially the development in newly-launched products that catches the eye of Sydbank analyst, Søren Løntoft Hansen.

“In these quarterly reports you can see just how far down the patent cliff Lundbeck has come, and whether there are any crags – so to speak –that they can latch on to in the form of new drugs. And those crags are there. The new drugs they have launched in recent years are doing really well, so it is a good report with very positive subtexts – especially in terms of the development of new drugs, such as Xenazine, Sabril and Onfi,” he tells Medwatch, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier